Gamma-aminobutyric acid type A receptor/glycine receptor complex (GABA-A/GlyR complex (commonly, GABA-A and GlyR are used for the individual receptors; no widely accepted abbreviation for the combined complex))

The gamma‑aminobutyric acid type A receptor (GABA‑A) and the glycine receptor (GlyR) are both pentameric ligand-gated ion channels that mediate fast synaptic inhibition in the central nervous system. They share structural similarities as members of the Cys-loop superfamily but differ in their primary ligands—GABA for GABA‑A and glycine for GlyR. Each consists of five subunits forming an anion-selective pore permeable primarily to chloride ions. Activation leads to hyperpolarization and decreased neuronal excitability. While there is evidence that these two types of inhibitory receptors can co-localize at some synapses—especially during development—and may functionally interact through shared scaffolding proteins or signaling pathways, they do not typically form a stable biochemical “receptor complex” as implied by this target name. Instead, they represent parallel systems contributing to overall inhibitory tone within neural circuits[3]. Both have been extensively targeted pharmacologically for conditions such as anxiety, epilepsy, insomnia, muscle spasticity, anesthesia induction/maintenance (for GABA‑A), and rare genetic hyperekplexia syndromes (for GlyR)[1][2]. Their modulation carries risks including sedation and respiratory depression. In summary: The “Central nervous system GABA‑A receptor/glycine receptor complex” refers imprecisely to two distinct but related inhibitory neurotransmitter receptors rather than a single molecular entity. Each is an important therapeutic target individually; together they represent key components of CNS inhibition but should be considered separately when structuring data about drug targets.[1][2][3]

Other names

Gamma-aminobutyric acid type A receptor (GABA-A receptor)Glycine receptor (GlyR)GABAAGlyR

Positive allosteric modulation to enhance inhibitory chloride currents (benzodiazepines, barbiturates); Direct agonism/antagonism at ligand-binding sites